Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oragenics Inc OGEN

Healthcare Biotechnology
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for... see more

Recent & Breaking News (NYSEAM:OGEN)

Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Business Wire March 14, 2023

Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

Business Wire March 8, 2023

Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

Business Wire March 1, 2023

Oragenics, Inc. Regains Compliance with NYSE American

Business Wire February 3, 2023

Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split

Business Wire December 23, 2022

Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate

Business Wire December 22, 2022

Oragenics, Inc. Receives NYSE American Notice

Business Wire December 20, 2022

Oragenics, Inc. Announces New Chair

Business Wire December 19, 2022

Oragenics to Participate in the 2022 BioFlorida Annual Conference

Business Wire October 24, 2022

Oragenics Issues Letter to Shareholders

Business Wire September 30, 2022

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Business Wire August 24, 2022

Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

Business Wire June 23, 2022

Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports

Business Wire June 14, 2022

Oragenics Issues Letter to Shareholders

Business Wire May 17, 2022

Oragenics to Participate at the World Vaccine Congress Washington 2022

Business Wire April 18, 2022

Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses

Business Wire April 6, 2022

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

Business Wire March 25, 2022

Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

Business Wire March 22, 2022

Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1

Business Wire March 10, 2022

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

Business Wire March 3, 2022